

# Amendment Tool

v1.2 11 Jun 2020

For office use

QC: No

## Section 1: Project information

Short project title*:	RECOVERY Trial			
IRAS project ID* (or REC reference if no IRAS project ID is available):	281712			
Sponsor amendment reference number*:	Substantial Amendment 13			
Sponsor amendment date* (enter as DD/MM/YY):	26 January 2021			
Summary of amendment including justification*:	We wish to (i) introduce a new comparison to the main randomisation (in a new part D) to assess baricitinib versus standard care alone; and (ii) introduce a new arm to the second randomisation for children so that this now assesses anakinra (new IMP), tocilizumab and standard care alone. We have completed the assessment of tocilizumab in adults so they are no longer eligible for the second randomisation. We have also completed recruitment to the convalescent plasma comparison (details below). A detailed justification is included.			
Project type:	<input checked="" type="radio"/> Specific study <input type="radio"/> Research tissue bank <input type="radio"/> Research database			
Has the study been reviewed by a UKECA-recognised Research Ethics Committee (REC) prior to this amendment?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
What type of UKECA-recognised Research Ethics Committee (REC) review is applicable?:	<input checked="" type="radio"/> NHS/HSC REC <input type="radio"/> Ministry of Defence (MoDREC)			
Is all or part of this amendment being resubmitted to the Research Ethics Committee (REC) as a modified amendment?	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Where is the NHS/HSC Research Ethics Committee (REC) that reviewed the study based?:	England	Wales	Scotland	Northern Ireland
	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Was the study a clinical trial of an investigational medicinal product (CTIMP) OR does the amendment make it one?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
Was this clinical trial of an investigational medicinal product (CTIMP) processed under the Combined Ways of Working (CWOW) pilot?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study receive Pharmacy Assurance?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
Was the study a clinical investigation or other study of a medical device OR does the amendment make it one?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve the administration of radioactive substances, therefore requiring ARSAC review, OR does the amendment introduce this?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve the use of research exposures to ionising radiation (not involving the administration of radioactive substances) OR does the amendment introduce this?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve adults lacking capacity OR does the amendment introduce this?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
Did the study involve access to confidential patient information without consent OR does the amendment introduce this?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve prisoners OR does the amendment introduce this?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve NHS/HSC organisations prior to this amendment?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
Did the study involve non-NHS/HSC organisations OR does the amendment introduce them?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
	England	Wales	Scotland	Northern Ireland
Lead nation for the study:	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Which nations had participating NHS/HSC organisations prior to this amendment?	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Which nations will have participating NHS/HSC organisations after this amendment?	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

## Section 2: Summary of change(s)

What do you want to update?:	<input checked="" type="radio"/> Project information <input type="radio"/> New site/PI only
------------------------------	--

**Please note:** Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the amendment tool as three separate changes. A list of all possible changes is available on the "Glossary of Changes" tab. To add another change, tick the "Add another change" box.

Change 1				
Area of change (select)*:	Study Design			
Specific change (select - only available when area of change is selected first)*:	New arm - Addition of a study arm or placebo/control group			
Further information (free text):	We wish to introduce part D to the main randomisation which will compare baricitinib with standard care alone. This will be available for adults, and children >=2 years old with COVID-19 pneumonia. This IMP has been recommended by the DHSC's COVID-19 Therapeutics Advisory Panel.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some?:	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☒

Change 2				
Area of change (select)*:	Study Design			
Specific change (select - only available when area of change is selected first)*:	New arm - Addition of a study arm or placebo/control group			
Further information (free text):	We wish to introduce a new IMP to the second randomisation for children. This will become anakinra (new IMP) or tocilizumab or standard care alone. This IMP has been added after detailed consultations within the paediatric community.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some?:	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☒

Change 3				
Area of change (select)*:	Study Design			
Specific change (select - only available when area of change is selected first)*:	Other significant change to study design that can be implemented within existing resource in place at participating organisations - Please specify in the free text below			
Further information (free text):	We wish to remove tocilizumab from the second randomisation for adults as this assessment has now been completed.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some?:	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☒

Change 4				
Area of change (select)*:	Study Design			

Specific change (select - only available when area of change is selected first)*:	Inclusion/exclusion criteria - Minor change unlikely to affect safety or scientific value of study			
Further information (free text):	We have added a requirement for a pregnancy test for women of child-bearing potential so that such women may be included in the baricitinib, colchicine and anakinra arms if they are not pregnant.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some?:	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☒

Change 5				
Area of change (select)*:	Study Design			
Specific change (select - only available when area of change is selected first)*:	Inclusion/exclusion criteria - Significant change (e.g. to age range) likely to affect safety or scientific value of study			
Further information (free text):	We wish to allow all adult women to be potentially eligible for the colchicine comparison because we are now including a pregnancy test (change 4 above). Only participants who are pregnant (or who decline a pregnancy test and have child-bearing potential) would be excluded from colchicine comparison (and similarly baricitinib or anakinra).			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some?:	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☒

Change 6				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Other minor document change that can be implemented within existing resource in place at participating organisations - Please specify in the free text below			
Further information (free text):	We wish to remove the recommendation that pregnant women who have received REGN10933+REGN10987 should not receive live vaccines. A full justification is included.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some?:	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☒

Change 7	
Area of change (select)*:	Study Design
Specific change (select - only available when area of change is selected first)*:	Other significant change to study design that can be implemented within existing resource in place at participating organisations - Please specify in the free text below

Further information (free text):	The Data Monitoring Committee advised that no further participants be recruited into the convalescent plasma comparison so this was stopped on 15th January 2021 and has now been removed from the protocol and associated documents. The DMC also recommended that the trial no longer needs to collect early safety information for any participants in the antibody-based comparison so this section has been removed from the protocol.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some?:	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☒

Change 8				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Other significant document change that can be implemented within existing resource in place at participating organisations - Please specify in the free text below			
Further information (free text):	We wish to provide guidance to participants who have received an antibody-based treatment about the optimal timing of vaccination. Language has been added to the protocol and PIS.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some?:	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☒

Change 9				
Area of change (select)*:	CTIMP IMP			
Specific change (select - only available when area of change is selected first)*:	Other - Please specify in the free text below			
Further information (free text):	Due to unexpected demand, NHS supplies of methylprednisolone are limited and it may not be available for children presenting with PIMS-TS. Our paediatric working group has considered this and recommends substituting dexamethasone should this occur.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some?:	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☒

Change 10	
Area of change (select)*:	Study Documents
Specific change (select - only available when area of change is selected first)*:	Correction of typographical errors

Further information (free text):

Applicability:

England

Wales

Scotland

Northern Ireland

Where are the participating NHS/HSC organisations located that will be affected by this change?\*



Will all participating NHS/HSC organisations be affected by this change, or only some?:



All



Some

### Section 3: Declaration(s) and lock for submission

#### Declaration by the Sponsor or authorised delegate

- I confirm that the Sponsor takes responsibility for the completed amendment tool
- I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf

Name [first name and surname]\*:

Elaine Chick

Email address\*:

ctrg@admin.ox.ac.uk

#### Lock for submission

**Please note:** This button will only become available when all mandatory (\*) fields have been completed. When the button is available, clicking it will generate a PDF copy of the completed amendment tool that can be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, refer to the "Submission Guidance" tab for further information about the next steps for the amendment.

### Section 4: Review bodies for the amendment

**Please note:** This section is for **information only**. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

	Review bodies																	Category:	
	UK wide:					England and Wales:				Scotland:			Northern Ireland:						
	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	HMPPS	HRA and HCRW Approval	REC (AWIA)	PBPP	SPS (RAEC)	National coordinating function	HSC REC	HSC Data Guardians	Prisons		National coordinating function
Change 1:	Y	Y				(Y)				(Y)				(Y)				(Y)	A
Change 2:	Y	Y				(Y)				(Y)				(Y)				(Y)	A
Change 3:	Y	Y				Y				Y				Y				Y	C
Change 4:	N	N				(Y)				(Y)				(Y)				(Y)	A
Change 5:	Y	Y				(Y)				(Y)				(Y)				(Y)	A
Change 6:	N	N				(Y)				(Y)				(Y)				(Y)	C
Change 7:	Y	Y				Y				Y				Y				Y	C
Change 8:	Y	N				Y				Y				Y				Y	C
Change 9:	Y	Y				Y				Y				Y				Y	A
Change 10:	N	N				N				N				N				N	N/A
Overall reviews for the amendment:																			
Full review:	Y	Y				Y				Y				Y				Y	
Notification only:	N	N				N				N				N				N	

Overall amendment type:	Substantial for review
Overall Category:	A